Core Points - Apollomics Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement for its Class A ordinary shares, which must be at least $1.00 per share [1][2] - The extension allows the company until January 13, 2025, to meet the compliance requirement, with the possibility of delisting if it fails to do so [2][3] - The company is actively monitoring its share prices and evaluating options to regain compliance, although there is no guarantee of success [3] Company Overview - Apollomics Inc. is a late-stage clinical biopharmaceutical company focused on developing oncology therapies for difficult-to-treat and treatment-resistant cancers [1][4] - The company's lead product, vebreltinib (APL-101), is a selective c-Met inhibitor currently in Phase 2 trials for non-small cell lung cancer and other advanced tumors [4] - Another key product, uproleselan (APL-106), is an E-Selectin antagonist in Phase 1 and Phase 3 trials for acute myeloid leukemia and other hematologic cancers [4]
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement